Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries
CONCLUSION: Most individuals with SLCT fare well, though specific risk factors such as mesenchymal heterologous elements are associated with poor prognosis. We also highlight the role of DICER1 surveillance in early detection of SLCT, facilitating stage IA resection.PMID:38657450 | DOI:10.1016/j.ygyno.2024.04.005 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 24, 2024 Category: Cancer & Oncology Authors: Alexander T Nelson Anne K Harris Dave Watson Junne Kamihara Kenneth S Chen Jennifer N Stall Kyle M Devins Robert H Young Damon R Olson Paige H R Mallinger Sarah G Mitchell Lindsey M Hoffman Gail Halliday Amina M Suleymanova Julia L Glade Bender Yoav H Mes Source Type: research
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
CONCLUSIONS: CGR during SCS is associated with improved PFS2 compared to suboptimal resection. Prospective randomized trials are warranted to elucidate the role of SCS as more therapeutics become available.PMID:38640773 | DOI:10.1016/j.ygyno.2024.03.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Sarah Ehmann Clarissa Lam Qin Zhou Alexia Iasonos Rachel N Grisham William P Tew Roisin E O'Cearbhaill Kara Long Roche Oliver Zivanovic Yukio Sonoda Dennis S Chi Ginger J Gardner Source Type: research
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma
CONCLUSION: These data demonstrate an abnormal karyometric signature in STICs that may extend beyond the STIC, potentially providing an opportunity for early detection of fallopian tube neoplasia.PMID:38640774 | DOI:10.1016/j.ygyno.2024.04.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Gustavo C Rodriguez Michael Yozwiak Omar L Nelson Hao Helen Zhang Ahyoung Amy Kim William Watkin Jennifer K Barton David S Alberts Source Type: research
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
CONCLUSIONS: CGR during SCS is associated with improved PFS2 compared to suboptimal resection. Prospective randomized trials are warranted to elucidate the role of SCS as more therapeutics become available.PMID:38640773 | DOI:10.1016/j.ygyno.2024.03.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Sarah Ehmann Clarissa Lam Qin Zhou Alexia Iasonos Rachel N Grisham William P Tew Roisin E O'Cearbhaill Kara Long Roche Oliver Zivanovic Yukio Sonoda Dennis S Chi Ginger J Gardner Source Type: research
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma
CONCLUSION: These data demonstrate an abnormal karyometric signature in STICs that may extend beyond the STIC, potentially providing an opportunity for early detection of fallopian tube neoplasia.PMID:38640774 | DOI:10.1016/j.ygyno.2024.04.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Gustavo C Rodriguez Michael Yozwiak Omar L Nelson Hao Helen Zhang Ahyoung Amy Kim William Watkin Jennifer K Barton David S Alberts Source Type: research
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging
Gynecol Oncol. 2024 Apr 13;186:94-103. doi: 10.1016/j.ygyno.2024.04.008. Online ahead of print.ABSTRACTThe Cancer Genome Atlas (TCGA) Research Network described 4 molecular subgroups of endometrial carcinomas with different outcome: 1) POLE ultramutated endometrioid carcinomas which have an indolent behavior; 2) microsatellite instability hypermutated endometrioid carcinomas associated with intermediate prognosis; 3) copy-number low endometrioid carcinomas also with intermediate prognosis; and 4) copy-number high predominantly serous (non-endometrioid) but also serous-like endometrioid carcinomas, almost always carrying TP...
Source: Gynecologic Oncology - April 14, 2024 Category: Cancer & Oncology Authors: I ñigo Espinosa Emanuela D'Angelo Jaime Prat Source Type: research
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging
Gynecol Oncol. 2024 Apr 13;186:94-103. doi: 10.1016/j.ygyno.2024.04.008. Online ahead of print.ABSTRACTThe Cancer Genome Atlas (TCGA) Research Network described 4 molecular subgroups of endometrial carcinomas with different outcome: 1) POLE ultramutated endometrioid carcinomas which have an indolent behavior; 2) microsatellite instability hypermutated endometrioid carcinomas associated with intermediate prognosis; 3) copy-number low endometrioid carcinomas also with intermediate prognosis; and 4) copy-number high predominantly serous (non-endometrioid) but also serous-like endometrioid carcinomas, almost always carrying TP...
Source: Gynecologic Oncology - April 14, 2024 Category: Cancer & Oncology Authors: I ñigo Espinosa Emanuela D'Angelo Jaime Prat Source Type: research
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging
Gynecol Oncol. 2024 Apr 13;186:94-103. doi: 10.1016/j.ygyno.2024.04.008. Online ahead of print.ABSTRACTThe Cancer Genome Atlas (TCGA) Research Network described 4 molecular subgroups of endometrial carcinomas with different outcome: 1) POLE ultramutated endometrioid carcinomas which have an indolent behavior; 2) microsatellite instability hypermutated endometrioid carcinomas associated with intermediate prognosis; 3) copy-number low endometrioid carcinomas also with intermediate prognosis; and 4) copy-number high predominantly serous (non-endometrioid) but also serous-like endometrioid carcinomas, almost always carrying TP...
Source: Gynecologic Oncology - April 14, 2024 Category: Cancer & Oncology Authors: I ñigo Espinosa Emanuela D'Angelo Jaime Prat Source Type: research
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
CONCLUSIONS: Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need for therapeutic studies in patients with OCCC.PMID:38603953 | DOI:10.1016/j.ygyno.2024.03.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Lilian T Gien Danielle M Enserro Matthew S Block Steven Waggoner Linda R Duska Andrea E Wahner-Hendrickson Premal H Thaker Floor Backes Michael Kidd Carolyn Y Muller Paul A DiSilvestro Allan Covens David M Gershenson Kathleen N Moore Carol Aghajanian Robe Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Adoptive T cell therapy for ovarian cancer
Gynecol Oncol. 2024 Apr 10;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Online ahead of print.ABSTRACTAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therap...
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Sarah B Gitto Chibuike J N Ihewulezi Daniel J Powell Source Type: research
Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment
CONCLUSION: These data suggest that patient characteristics and surgical procedures related to cesarean hysterectomy for placenta accreta spectrum differ based on surgeon specialty. Gynecologic oncologists appear to manage more severe forms of placenta accreta spectrum. Regardless of surgeon's specialty, surgical morbidity of cesarean hysterectomy for placenta accreta spectrum is significant.PMID:38603956 | DOI:10.1016/j.ygyno.2024.04.004 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Koji Matsuo Yongmei Huang Shinya Matsuzaki Andrew Vallejo Joseph G Ouzounian Lynda D Roman Fady Khoury-Collado Alexander M Friedman Jason D Wright Source Type: research
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
CONCLUSIONS: Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need for therapeutic studies in patients with OCCC.PMID:38603953 | DOI:10.1016/j.ygyno.2024.03.027 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Lilian T Gien Danielle M Enserro Matthew S Block Steven Waggoner Linda R Duska Andrea E Wahner-Hendrickson Premal H Thaker Floor Backes Michael Kidd Carolyn Y Muller Paul A DiSilvestro Allan Covens David M Gershenson Kathleen N Moore Carol Aghajanian Robe Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Adoptive T cell therapy for ovarian cancer
Gynecol Oncol. 2024 Apr 10;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Online ahead of print.ABSTRACTAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therap...
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Sarah B Gitto Chibuike J N Ihewulezi Daniel J Powell Source Type: research
